What is the significance of an anti‑cardiolipin IgG level of 24 GPL and how should it be evaluated and managed?

Anti-Cardiolipin IgG 24 GPL: Clinical Significance and Management

An anti-cardiolipin IgG level of 24 GPL is a low-to-moderate positive result that requires confirmation testing in at least 12 weeks and complete antiphospholipid antibody panel evaluation before making any clinical decisions. 1

Interpretation of the Result

• A value of 24 GPL falls in the "weak positive" range according to the most recent 2025 ISTH guidelines, which define moderate positivity as ≥40 GPL units 1, 2

• This level sits above the typical 99th percentile cutoff (which ranges from 13-21 GPL across different assays and populations) but below the 40 GPL threshold used in ACR/EULAR classification criteria 2, 3, 4

• Low positive results around cutoff values must be interpreted with extreme caution due to assay imprecision of up to 10%, meaning values near thresholds may fluctuate between positive and negative on repeat testing 1

Clinical Significance and Risk Assessment

• Isolated anti-cardiolipin antibodies show disputed clinical relevance and may reflect antibodies directed against cardiolipin itself rather than β2-glycoprotein I-dependent antibodies, which are the pathogenic form 1

• The clinical significance depends entirely on the complete antiphospholipid antibody profile:

  • Triple positivity (lupus anticoagulant + aCL + aβ2GPI) carries the highest thrombotic risk 2
  • Double positivity indicates intermediate risk 2
  • Single aCL positivity alone has poor predictive value for thrombotic events 1

• IgG isotype has stronger association with thrombosis than IgM, with odds ratios of 3.69 for thrombosis when using ROC-derived cutoffs around 17 GPL 5, 6

Required Evaluation Steps

Immediate Testing Requirements

• Complete the full antiphospholipid antibody panel on the same sample: 1, 2

  • Lupus anticoagulant (LAC) testing using phospholipid-dependent clotting assays
  • Anti-β2-glycoprotein I (aβ2GPI) IgG and IgM
  • Anti-cardiolipin (aCL) IgM

• Testing for lupus anticoagulant is mandatory as it is the strongest predictor of both thrombotic and obstetric complications, and 25% of APS patients may have isolated aCL that would be missed without complete panel testing 1, 7

Confirmation Testing Protocol

• Repeat all positive tests in exactly 12 weeks (not less) to distinguish persistent from transient antibodies, as transient positivity occurs with infections and drugs 1

• Avoid testing during specific conditions that produce unreliable results: 1, 2

  • Active anticoagulation therapy (warfarin, DOACs)
  • Acute thrombotic events
  • Pregnancy (antibody levels fluctuate, with 25% of LA-positive patients becoming negative in second/third trimester)
  • Immediate post-thrombotic period (antibody levels may decrease due to deposition at thrombotic sites)

Clinical Context Assessment

• Evaluate for clinical manifestations of antiphospholipid syndrome:

  • History of arterial or venous thrombosis 2
  • Pregnancy morbidity (recurrent early losses, late pregnancy loss, severe preeclampsia) 1, 3
  • Thrombocytopenia 5, 6

• Screen for underlying autoimmune disease, particularly systemic lupus erythematosus, as aCL positivity is more prevalent in secondary APS 1

Management Algorithm

If Antibodies Are NOT Persistent (Negative on Repeat Testing)

• No diagnosis of APS can be made - transient positivity does not meet classification criteria 1
• Consider infectious or drug-related causes of transient antibodies 1
• No specific thromboprophylaxis indicated based on antibodies alone

If Antibodies ARE Persistent (Positive on Repeat Testing at ≥12 Weeks)

With Clinical Manifestations (Thrombosis or Pregnancy Morbidity):

• Classify as definite APS if criteria are met (persistent antibodies + clinical events) 2
• Initiate long-term anticoagulation for thrombotic events per standard APS management
• Implement pregnancy management protocols (aspirin ± heparin) for obstetric APS 2

Without Clinical Manifestations (Asymptomatic):

• Risk stratification based on complete antibody profile: 2

  • Triple positive: Highest risk, consider primary thromboprophylaxis in high-risk situations
  • Double positive: Intermediate risk, individualized approach
  • Single aCL IgG at 24 GPL: Low risk, generally observation only

• Do not diagnose APS without clinical criteria - antibody positivity alone is insufficient 2

Critical Pitfalls to Avoid

• Never make treatment decisions based on a single positive test - persistence must be documented 1

• Do not assume all aCL antibodies are pathogenic - only β2GPI-dependent aCL antibodies are clinically significant 2

• Recognize that 6.6% of patients with clinical APS may be negative for classic antibodies (LAC and aCL) but positive for other phospholipid antibodies 5

• Be aware of the 10% assay imprecision - a value of 24 GPL could represent anywhere from 21.6 to 26.4 GPL on repeat testing 1

• Consider that isolated moderate-positive aCL (without LAC or aβ2GPI) has limited predictive value and may lead to overdiagnosis if not interpreted in proper clinical context 1